E3™ research into peptides and nutraceuticals has yielded a plethora of new treatment possibilities to combat aging, treat the remnants of previous bacterial and viral infections and address cognitive shortcomings.
Through our partnership with Vantage ASC, E3™ is developing adjunctive therapies which can potentiate existing chemotherapy and radiation treatments and help to reduce common unpleasant and sometimes debilitating side effects. In addition, E3™ is researching and creating custom drug and nutraceutical compounding/blending therapies for treating many existing diseases.
